Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Alteration in tumor suppressor gene TP53 plays key role early in development of bone cancer

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project found mutations in the tumor suppressor gene TP53 in 90 percent of osteosarcomas, suggesting the alteration plays a key role early in development of the bone cancer.

4 Apr 2014

Study looks at ability of nontoxic molecules to store harmful alpha emitting radioisotopes

Researchers have discovered that microscopic "bubbles" developed at Kansas State University are safe and effective storage lockers for harmful isotopes that emit ionizing radiation for treating tumors.

3 Apr 2014

RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial photodynamic therapy (I-PDT) to recurrent tumors of the head and neck.

2 Apr 2014

Brainlab, Mobius Imaging announce CE Mark approval for Airo Mobile Intraoperative CT

Brainlab, a global leader in medical technology and Mobius Imaging, developer of advanced imaging technologies, announced today CE Mark approval for Airo Mobile Intraoperative CT. The CE Mark allows Brainlab to begin installation of the systems sold in the European Union.

1 Apr 2014

Research findings offer insight into helping cancer patients assess treatment risk

UT Southwestern Medical Center researchers are developing a new predictive tool that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help.

28 Mar 2014

Scientists identify two markers that predict patient's resistance to radiation therapy for cancer

An international team of researchers, led by Beaumont Health System's Jan Akervall, M.D., Ph.D., looked at biomarkers to determine the effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck.

28 Mar 2014

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

American Shared Hospital Services, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the fourth quarter and 2013.

27 Mar 2014

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.

26 Mar 2014

Radiation therapy fights cancer in more ways than one

Radiation therapy fights cancer in more ways than one. Not only does it force cancer cells to self-destruct, but several studies demonstrate that it also activates the immune system to attack tumor cells.

25 Mar 2014

High-volume medical centers improve gynecologic cancer survival

Women with ovarian and other gynecologic cancers live significantly longer when they receive care at hospitals that treat a large number of patients with these conditions, according to research on more than 850,000 women.

25 Mar 2014

Women with BRCA1 mutations may have increased risk for rare types of aggressive uterine cancer

Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings being presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Tampa, Fla., March 22-25.

25 Mar 2014

Ascend Biopharmaceuticals reports favourable results from TG1042 Phase 2 study for CBCL treatment

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has today announced the publication of a report utilising TG1042 (ASN-002) for the treatment of Cutaneous B-Cell Lymphoma (CBCL), in the journal PLOS ONE.

21 Mar 2014

Investigational vaccine reduces number of tumors in mice with lung cancer

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted the immune response and reduced the number of tumors in mice with lung cancer.

20 Mar 2014

RaySearch signs distribution agreement with AlphaXRT for RayStation

RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation in Australia and New Zealand from April 1, 2014.

19 Mar 2014

Primary ADT proves ineffective in early stage prostate cancer patients

A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.

19 Mar 2014

iCAD prices underwritten public offering of 2,400,000 shares of common stock

iCAD, Inc. ("iCAD"), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has priced a registered firm commitment underwritten public offering of 2,400,000 shares of its common stock at a price to public of $11.00 per share.

12 Mar 2014

MUSC, Alliance Oncology announce strategic radiation therapy affiliation

The Medical University of South Carolina (MUSC), one of the nation's top academic health science centers, and Alliance Oncology, a division of Alliance HealthCare Services, Inc., announce a newly formed affiliation designed to strengthen and expand MUSC's Hollings Cancer Center as the radiation therapy market leader in Charleston, South Carolina.

12 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.

6 Mar 2014

Radiation Therapy News and Research

Further Reading

Alteration in tumor suppressor gene TP53 plays key role early in development of bone cancer

Study looks at ability of nontoxic molecules to store harmful alpha emitting radioisotopes

RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

Brainlab, Mobius Imaging announce CE Mark approval for Airo Mobile Intraoperative CT

Research findings offer insight into helping cancer patients assess treatment risk

Scientists identify two markers that predict patient's resistance to radiation therapy for cancer

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

Radiation therapy fights cancer in more ways than one

High-volume medical centers improve gynecologic cancer survival

Women with BRCA1 mutations may have increased risk for rare types of aggressive uterine cancer

Ascend Biopharmaceuticals reports favourable results from TG1042 Phase 2 study for CBCL treatment

Investigational vaccine reduces number of tumors in mice with lung cancer

RaySearch signs distribution agreement with AlphaXRT for RayStation

Primary ADT proves ineffective in early stage prostate cancer patients

iCAD prices underwritten public offering of 2,400,000 shares of common stock

MUSC, Alliance Oncology announce strategic radiation therapy affiliation

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Antares Pharma announces launch of OTREXUP to Dermatologists

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News